Dr. William Greene has 20 years’ experience in the biotechnology industry as an operating executive, clinician, investor, and entrepreneur. Since 2014, he has been CEO of Iconic Therapeutics. Prior to Iconic, he was a Managing Director with MPM Capital, where he continues as a Venture Partner.

Bill’s board and investment experience includes Alnara (acquired, Eli Lilly), Alsius (acquired, Zoll), Barrier Therapeutics (acquired Steifel), Cotherix (acquired, Actelion), Idun Pharmaceuticals (acquired, Pfizer) and Intercell AG. Prior to joining MPM, Dr. Greene was at Genentech where he was a Senior Clinical Scientist and Epidemiologist with responsibilities in clinical strategy, trial design and market planning in several therapeutic areas across all phases of drug development, including clinical development of Lucentis®. His clinical training was at Yale Medical School and he was for several years an Assistant Professor of Medicine at the University of California, San Francisco where he cared for patients and was an active member of the teaching staff at San Francisco General Hospital.

Dr. Greene received his B.A. from Wesleyan University and M.D. from UCSF. He was Board Certified in Internal Medicine, was a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology) and a Howard Hughes Medical Institute Research Scholar at the NIH (neurobiology). He is co-founder of and Senior Advisor to Pear Therapeutics. He is the founding Chairman of the Board and head of the Investment Committee of the Global Health Investment Fund, a pioneering global health-oriented life science venture capital fund.